SSSouha Sahraoui

Souha Sahraoui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Souha Sahraoui has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinicopathological Characteristics and Prognostic Factors of Diffuse Infiltrating Glioma in Morocco: A Retrospective Single-Center Institutional Experience Under the 2021 WHO Classification

    by Oumaima Bouchra, Chaymae El Baha, Sara El Guendouzi, Amina Essalihi, Zineb Khadrouf, Khadija Khadiri, Souha Sahraoui, Reda Ben Mrid, Najat Bouchmaa, Rachid El Fatimy, et al.

  • Open Access

    Non-epithelial Ovarian Tumors: A Retrospective Analysis of 18 Cases and Literature Review

    by Salma Safi, Rania Salhi, Meriem Belhouari, Mouna Bourhafour, Souha Saharaoui

    Background: Non-epithelial ovarian tumors represent a rare and heterogeneous group of malignancies, accounting for a minority of ovarian cancers but occurring more frequently in young women. Because of their rarity and diverse clinical and histopathological profiles, these tumors remain less well characterized than epithelial ovarian cancers. Objectives: This study aimed to describe the epidemiological, clinical, paraclinical, and pathological characteristics of non-epithelial ovarian tumors, as well as assess therapeutic strategies and clinical outcomes, through a retrospective analysis of 18 cases. A complementary literature review was undertaken to contextualize our findings. Methods: A retrospective descriptive study was conducted at the Medical Oncology Department of CHU Ibn Rochd, Casablanca, including all histologically confirmed malignant non-epithelial ovarian tumors diagnosed between January 2021 and December 2022. Clinical presentation, imaging findings, tumor markers, histological subtypes, treatments, and outcomes were analyzed. Results: Of 140 ovarian cancer cases, 18 (12.8%) were non-epithelial tumors. Sex cord–stromal tumors were the most common (60%), followed by germ cell tumors. The mean age at diagnosis was 46.5 years for stromal tumors and 32.5 years for germ cell tumors. Abdominal distension (42%) and pelvic pain (30%) were the most frequent presenting symptoms. Imaging identified adnexal masses in most cases, consistent with reported high diagnostic performance of pelvic ultrasound and CT in ovarian tumor assessment [1,2]. Tumor marker evaluation showed variable elevations depending on tumor subtype, supporting existing recommendations for hCG, AFP, LDH, CA-125 and inhibin B testing [3,4]. All patients underwent surgery, with radical procedures performed in 60% of cases. First-line chemotherapy—primarily BEP or paclitaxel–carboplatin—was administered to 38% of patients, in accordance with current standards for germ cell tumors [4–6]. Complete remission at 6 months was achieved in 33% of cases, while relapse occurred in 22% and metastases in 16%. Overall survival in our series was 66%, lower than SEER- reported survival figures for similar tumor categories [7]. Conclusion: Non- epithelial ovarian tumors, although uncommon, require early diagnosis and individualized management due to their heterogeneous biological behavior and their predominance in young women. Fertility-sparing surgery and platinum-based chemotherapy remain key therapeutic strategies. Despite favorable initial responses, recurrence rates emphasize the importance of long-term surveillance and personalized treatment approaches.

  • Open Access

    Bladder Neuroendocrine Carcinoma: About Five Cases and Review of the Literature

    by Zaouit Maryam, Elkebir Asma, Oudad Fadwa, Jouhadi Hassan, Benchekroun Nadia, Sahraoui Souha, Benider Abdellatif


  • Open Access

    Extra Skeletal Myxoid Chondrosarcoma of the Foot: A Case Report

    by Sidki Sanaa, Zongo Pawendtaoré Esdras, Benchakroun Nadia, Chekrine Tarek, Bourhafour Mouna, Bouchbika Zineb, Jouhadi Hassan, Tawfiq Nezha, Sahraoui Souha, Benider Abdellatif

  • Open Access

    Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas

    by Imane Ait, Mouna Bourhafour, Meriem Haffadi, Zineb Bouchbika, Nadia Benchakroune, Hassan Jouhadi, Nezha Tawfiq, Souha Sahraoui, Abdellatif Benider

    Les tumeurs phyllodes (TP) du sein sont rares. Elles peuvent revêtir un caractère bénin, borderline ou malin. La forme maligne représente 20-30% des TP avec des métastases à distance dans 10-26% des cas. La chimiothérapie est l´une des principales armes thérapeutiques des tumeurs phyllodes métastatiques (TPM).

  • Open Access

    Optimization of the calculation time in simulation using the GATE/GEANT4 Monte Carlo of radiotherapy treatment plans for small fields

    by Meriem Tantaoui, Mustapha Krim, Ismail Ghazi, Zineb Sobhy, Othmane Kaanouch, Abdelkrim Kartouni, Souha Sahraoui

    Radiation therapy is one of the most widely used methods of treating cancer. One of the therapeutic gains of this method is to save in terms of calculation time during treatment planning, the variance reduction method is one of the most used to reduce the calculation time except that there are other alternatives to be able to optimize as much as possible, hence the interest of this study. In this work, we compared by Monte-Carlo simulation the flattened and unflattened 6 MV photon beams of the VARIAN Clinac 2100 linear accelerator. All the elements of the accelerator were simulated and allowed us to reproduce very close to reality. The doses obtained by simulation were taken in a tank of water under reference conditions, source to surface distance (SSD) of 100 cm, the arm at 0 ° and for a field variation of 2 x 2 cm2, 3 x 3 cm2, 4 x 4 cm2, 5 x 5 cm2, 10 x 10 cm2, 20 x 20 cm2, 30 x 30 cm2, 40 x 40 cm2. For each field, we calculated using a beam with a flattening filter (FF) and another beam with flattening filter-free (FFF). The calculation time of all these simulations was recorded. The results showed that the shape of the dose profiles changes according to the FF and FFF mode with a very interesting change for fields greater than 5 x 5 cm2 and almost similar profiles for the fields 2 x 2 cm2, 3 x 3 cm2, 4 x 4 cm2, 5 x 5cm2. The region between 80% and 100% of doses for beams with FF contributes to dose uniformity while for FFF fields gives the appearance of symmetry of dose distribution for all fields combined. On the depth dose curves (PDD) the dose at the entry into FFF mode was greater than that of FF mode leading to an increase in the influence of photons, the latter thus important on the increase in dose rate. The computation time in FF mode is higher by a proportion factor of 0.85 to 7.36 compared to the FFF mode respectively by going from the field 2 x 2 cm2 to 40 x 40 cm2. This comparison leads to being able to neglect the flattening filter for fields smaller than 5 x 5 cm2 since it has no impact on the processing field but has a great impact on the calculation time and to have a mode without this filter for fields smaller than 5 x 5 cm2 leads to an optimization of the computation time of 1.35 times compared to the FF mode.


  • Open Access

    Cancer management challenge in a developing country in COVID-19 pandemic: reflection of a group of Moroccan oncologists

    by Hind Mrabti, Narjiss Berrada, Ghislaine Raiss, Hamza Ettahri, Halima Abahssain, Mouna Bourhafour, Souha Sahraoui, Hassan Errihani

    Management of cancer patients during the COVID-19 pandemic is a worldwide challenge – in particular in developing countries where the risk of saturation of health facilities and intensive care beds...


  • Dosimetric Comparison of 3D Conformal Radiotherapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT®) in Prostate Cancer

    by Meriem Tantaoui, Mustapha Krim, Ismail Ghazi, Zineb Sobhy, Abdelkrim Kartouni, Hamid Chakir, Abdenebi El Moutawakkil, Souha Sahraoui


  • Open Access

    Cancer du sein chez l'homme: à propos de 40 cas et revue de la littérature

    by Meriem Elbachiri, Safini Fatima, Zineb Bouchbika, Nadia Benchekroun, Hassan Jouhadi, Nezha Tawfiq, Souha Sahraoui, Abdellatif Benider

    Le cancer du sein chez l'homme est une affection rare repr?sentant environ 1% de tous les cancers du sein et moins de 1% de l'ensemble des n?oplasies masculines. L'objectif de notre ?tude est de d?crire les diff?rents aspects cliniques, histologique, pronostic et th?rapeutiques de cette tumeur rare afin de contribuer ? l'am?lioration de la prise en charge de cette affection. Il s'agit d'une ?tude r?trospective portant sur 40 patients collig?s au Centre Mohamed VI pour le traitement des cancers de Casablanca de Janvier 2000 ? D?cembre 2012. L'?ge m?dian a ?t? de 62 ans, le d?lai moyen de consultation a ?t? de 12 mois, l'autopalpation d'un nodule p?ri ar?olaire a ?t? le principal motif de consultation dans 90% des cas. Le carcinome canalaire infiltrant a ?t? le type histologique pr?dominant dans 90% des cas. La prise en charge th?rapeutique multimodale a consist? en une mastectomie suivie d'un traitement adjuvant ? type de chimioth?rapie, radioth?rapie et/ou hormonoth?rapie en fonction du stade de la tumeur et des caract?ristiques histologiques. Le suivi moyen a ?t? de 38 mois, l'?volution a ?t? caract?ris?e par une r?mission compl?te chez 16 patients (soit 40%), rechute locale chez 3 patients (soit 7.5%) et par une rechute m?tastatique chez 5 patients (soit 12.5%). Le site m?tastatique le plus fr?quent a ?t? l'os (62%), suivi par le poumon et le foie. Le d?c?s ?tait survenu chez 10 patients (25%). Le cancer du sein chez l'homme pr?sente des similitudes avec le cancer mammaire chez la femme. Mais il pr?sente aussi beaucoup de particularit?s, d'o? l'int?r?t de mener des ?tudes prospectives randomis?s ? plus large ?chelle afin d'am?liorer la prise en charge et le pronostic de cette affection dont l'impact psychosociale est consid?rable.